Working... Menu
Trial record 8 of 8 for:    "Gastric Cancer" | "Metronidazole"

Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01264822
Recruitment Status : Completed
First Posted : December 22, 2010
Last Update Posted : February 27, 2017
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )

Brief Summary:
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori

Condition or disease Intervention/treatment
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive Drug: Rabeprazole Sodium

Layout table for study information
Study Type : Observational
Actual Enrollment : 108 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Actual Study Start Date : January 13, 2011
Actual Primary Completion Date : February 29, 2016
Actual Study Completion Date : November 17, 2016

Group/Cohort Intervention/treatment
Treatment Arm 1 Rabeprazole Sodium Drug: Rabeprazole Sodium

The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.

The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.

If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg.

Primary Outcome Measures :
  1. Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori [ Time Frame: Every 3 months within the 1st year and every 6 months ]
  2. Transition rate to secondary therapy for eradication of Helicobacter pylori [ Time Frame: Every 6 months within the 1st year and every 12 months as needed ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hospitals and Clinics in Japan

Inclusion criteria:

  • gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphoma with Helicobacter pylori positive
  • The stages of MALT lymphoma are Lugano International Conference classification Stage I or II 1 and Wotherspoon grade 4 or 5

Exclusion criteria:

  • With diffuse large B-cell lymphoma
  • Have been treated to gastric mucosa-associated lymphoid tissue (MALT) lymphoma
  • Corresponding to contraindication of each drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01264822

Layout table for location information
Nagoya, Aichi, Japan
Hirosaki, Aomori, Japan
Kashiwa, Chiba, Japan
Matsuyama, Ehime, Japan
Fukuyama, Hiroshima, Japan
Sapporo, Hokkaido, Japan
Amagasaki-shi, Hyogo, Japan
Kobe, Hyogo, Japan
Hitachi, Ibaraki, Japan
Takamatsu, Kagawa, Japan
Isehara, Kanagawa, Japan
Sendai, Miyagi, Japan
Nagano-shi, Nagano, Japan
Suzaka, Nagano, Japan
Oita-shi, Oita, Japan
Yufu, Oita, Japan
Kurashiki, Okayama, Japan
Tsuyama, Okayama, Japan
Hirakata, Osaka, Japan
Osakasayama, Osaka, Japan
Takatsuki, Osaka, Japan
Matsue, Shimane, Japan
Hamamatsu, Shizuoka, Japan
Otawara-shi, Tochigi, Japan
Chuo, Tokyo, Japan
Itabashi, Tokyo, Japan
Minato-ku, Tokyo, Japan
Shinagawa-ku, Tokyo, Japan
Yamagata-shi, Yamagata, Japan
Ube, Yamaguchi, Japan
Fukuoka, Japan
Hiroshima, Japan
Kyoto, Japan
Nagasaki, Japan
Nara, Japan
Niigata, Japan
Okayama, Japan
Osaka, Japan
Saga, Japan
Tottori, Japan
Toyama, Japan
Yamaguchi, Japan
Sponsors and Collaborators
Eisai Co., Ltd.
Layout table for investigator information
Study Director: Katsuya Sugizaki Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.

Layout table for additonal information
Responsible Party: Eisai Co., Ltd. Identifier: NCT01264822     History of Changes
Other Study ID Numbers: PRT10T
First Posted: December 22, 2010    Key Record Dates
Last Update Posted: February 27, 2017
Last Verified: January 2017

Keywords provided by Eisai Inc. ( Eisai Co., Ltd. ):
Rabeprazole Sodium
Helicobacter pylori
stomach neoplasms

Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action